-SG1001 (Best-in-Class, Phase 2 processing):• Indication: Invasive Aspergillosis (50+% death rate fungal diseases in immunocompromised patients);• Position: The only 2 DHODHi in the clinical stage. Better safety than Amphotericin-B, addressing risks of azole resistance (e.g., to voriconazole) ;• SG1001 already secured a $14M+ deal for Greater China rights with Livzon, and now offer exclusive overseas out-licensing rights.-SG6001 (Differentiated Oral PCSK9 Inhibitor, IND submission in Q4 2026)• Indication: Hyperlipidemia (High LDL-C)• Position: World’ s 3rd oral PCSK9i after MK-0616 (Merck, Phase 3) and AZD0780 (AZ, Phase 3). Animal Model (hamster & rhesus monkey models) proves superior LDL-C lowering efficacy vs. MK-0616.• SG6001 offer global out-licensing or co-development rights.